Boehringer is focused on developing solutions for cognitive impairment. Credit: Raman Oza from Pixabay. Boehringer Ingelheim has announced that BI 425809 has improved cognition in stable adults with schizophrenia in a Phase II clinical trial. Results showed that the Gly-T1 inhibitor met its primary endpoint in the 12-week placebo-controlled trial.
